DENVER, Colo. (247marketnews.com) — Profound Medical (NASDAQ:PROF) may be approaching a pivotal moment and its preliminary third-quarter numbers suggest the market could be underestimating just how quickly its MRI-guided treatment platform is gaining commercial traction.
The company said Wednesday that it expects Q3 2026 revenue of $9.8 million to $10.0 million, a projected 85% to 89% increase year over year and nearly 300% sequential growth from the $2.5 million reported in the second quarter. More strikingly, the preliminary range is above analyst consensus. Gross margin is expected to top 70% for a second consecutive quarter.
That is potential evidence that Profound’s commercial model is beginning to scale.
“The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound,” CEO and Chairman Arun Menawat said, pointing to increased activity across both the company’s installed base and new customer accounts.
The backdrop makes the numbers even more interesting. Profound ended the second quarter with 84 TULSA-PRO systems installed, while management estimated its qualified sales pipeline for TULSA-PRO and Sonalleve at approximately $70 million. The company also reported that operating expenses declined 16% year over year in Q2 and reiterated its full-year 2026 revenue guidance.
Then there is the clinical and reimbursement story. Earlier this year, Profound reported positive safety and functional outcomes from its CAPTAIN randomized post-market trial comparing TULSA with robotic radical prostatectomy, while Humana began covering the TULSA Procedure. Johns Hopkins Medicine also began treating its first commercial prostate patient with TULSA-PRO in January, adding a major academic institution to the technology’s commercial footprint.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.